QR Pharma is a specialty pharmaceutical company founded to develop novel treatments for Alzheimer‘s Disease, (AD) Parkinson’s disease (PD) and other neurodegenerative disorders.
The economic burden and impact on wellness and quality of life for both patients and their caregivers of Alzheimer’s, Parkinson’s and other neurodegenerative disease is crushing. Today, existing drugs manage the symptoms and provide only marginal cost-benefit trade-offs. Our goal is to develop drugs that stop the progression of these diseases.
QR Pharma’s candidate medicine Posiphen® targets early stage Parkinson’s Disease as well as Alzheimer’s Disease and may stop or slow the progression of those diseases. Posiphen® reduces levels of amyloid precursor protein (APP), tau and α-Synuclein (aSYN), three proteins that can turn toxic and precipitate the onset of neurodegeneration. Posiphen® inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans. Posiphen® also shows promise in Huntington’s disease, Down Syndrome, Traumatic Brain Injury, and Post Operative Cognitive Decline.
BOARD OF DIRECTORS
Michael M. B. Hoffman
Chairman of the Board
Mr. Hoffman is a Partner of Riverstone Holdings LLC, where he is principally responsible for investments in power.
Maria L. Maccecchini PhD
Founder, President & CEO
Founded QR Pharma in May 2008 to develop better therapeutics for Alzheimer’s disease.
Claudine E. Bruck PhD
Board Member
Pharmaceutical executive and scientist with strong entrepreneurial drive.
Mark White
Board Member
A bio-pharmaceutical executive with global marketing, business development and sales experience at Pfizer & Abbott and Bayer.
Bob Whelan
Board Member
Mr. Whelan has been President of Whelan & Company, LLC, providing financial consulting, valuation and strategic services to public and private companies in the technology, healthcare and alternative energy industries.
SCIENTIFIC ADVISORY BOARD
Sidney Strickland PhD
Chairman, SAB
Dr.Sidney Strickland, Chairman of the QR Pharma SAB and Professor of Neurology and Genetics at Rockefeller University.
Peter Davies PhD
SAB Member
Peter Davies PhD, is the director of the Litwin-Zucker Research Center for The Study of Alzheimer’s Disease and Memory Disorders associated with The Feinstein Institute for Medical Research.
William Mobley, M.D., PhD
SAB Member
A Distinguished Professor, Department of Neurosciences Florence Riford Chair for Alzheimer Research and Associate Dean for Neurosciences
Jeffrey L. Cummings MD
SAB Member
Dr. Cummings is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada, Cleveland.
Gregory Petsko PhD
SAB Member
Arthur J. Mahon Professor of Neurology and Neuroscience and Director, Helen and Robert Appel Alzheimer ’s Disease Research Institute.
Rudolph E. Tanzi PhD
SAB Member
Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.